Menactra Needs Long-Term Safety, Efficacy Studies Post-Approval – Cmte.

Sanofi-Aventis should commit to long-term efficacy and safety post-approval studies for its quadravalent meningococcal conjugate vaccine Menactra (MCV-4), an FDA advisory committee said